Candida Score for Invasive Candidiasis Risk Assessment

Introduction to the Candida Score

The Candida score is a clinical prediction tool that identifies critically ill patients at high risk for invasive candidiasis by combining clinical risk factors with colonization status, using a point-based system where a cutoff value ≥3 indicates patients who may benefit from empirical antifungal therapy, as recommended by clinical guidelines 1, 2

The Candida score assigns points based on the following risk factors: recent major surgery (1 point), multifocal Candida colonization (1 point), total parenteral nutrition (1 point), and severe sepsis/clinical sepsis (2 points), with a total score ranging from 0 to 5 points 1, 2
The score demonstrates sensitivity of 81% and specificity of 74% for predicting invasive candidiasis, with a cutoff value of ≥2.5 (typically rounded to ≥3 in clinical practice) 1, 2

Prospective validation studies have confirmed that patients with scores ≤3 have extremely low rates of invasive candidiasis, while those with scores of 4 or 5 have substantially higher rates, according to the World Journal of Emergency Surgery guidelines 1, 2
The score was originally developed in 2006 and validated in 2009, demonstrating a significant linear association between increasing score values and rates of invasive Candida infections 1, 2

The Candida score is most useful for ruling out invasive candidiasis rather than confirming it, given its high negative predictive value but poor positive predictive value, as noted by the World Journal of Emergency Surgery 1, 2
The score has high specificity but low sensitivity, meaning it may miss some patients with invasive candidiasis, and its performance may be limited in certain populations, including COVID-19 patients 1, 2
The score performs better when combined with biomarkers such as β-D-glucan (BDG), with one study showing that an integrated strategy using both Candida score >3 and BDG helped optimize antifungal therapy decisions without increasing mortality 1, 2

While the Candida score provides clinical guidance, it should ideally be combined with non-culture diagnostic methods such as β-D-glucan testing or mannan/anti-mannan antibody assays to improve diagnostic accuracy, as recommended by the World Journal of Emergency Surgery 1, 2
Blood cultures remain the gold standard but are negative in up to 50% of invasive candidiasis cases, highlighting the need for complementary diagnostic strategies 1, 2

The score has limited performance in certain populations, including COVID-19 patients, where one study found no difference in Candida scores between those with and without candidemia, according to the Journal of Microbiology, Immunology and Infection 3, 4